Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Vial 75 IU |
|
14010 | 6426 |
|
Vial 150 IU |
|
14011 | 6427 |
Related information
Dosage
See prescribing information for full details.
Indications
A treatment with FSH followed by the administration of human chronic gonadotrophin (HCG) is indicated to induce ovulation in infertile women suffering from hypothalamus or hypophyseal disorders and in spanomenorrhoeic or amenorrhoeic women. These women belong to the WHO group II and have generally already been treated with clomiphene citrate. Most have polycystic ovarian syndrome. FSH offers good therapeutic prospects for patients whose LH:FSH ratio has to be adjusted, avoiding an exogenous supply of LH. FSH may be used alone or in concomitance with human menopausal gonadotropin (HMG) in order to stimulate multiple follicular growth in patients involved in medicdbally assisted reproduction programs (IVF-ET, GIFT).
Contra-Indications
Pregnancy, lactation. Hypersensitivity to urofollitropin (FSH) or to any other ingredients of this medicdbine; enlarged ovaries or cysts not caused by a hormonal disorder (polycystic ovarian disease); bleeding of unknown cause; cancer of the ovaries, uterus or breast; abnormal swelling (tumor) of the pituitary gland or hypothalamus (brain); early menopause, malformation of the sexual organs or certain tumors of the womb that would make a normal pregnancy impossible.
Special Precautions
See prescribing information for full details.
Side Effects
See prescribing information for full details.
Drug interactions
See prescribing information for full details.